Latest Close
$8.07
Stock Hub
ACET
Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
-$2.25 (-21.80%)
Market Cap
$75,439,976.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$6.01 to $17.44
Target Mean Price
$34.83
Beta
1.51
Trailing P/E
Not available
Forward P/E
-1.98
Price / Book
0.54
Company Overview
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.